Douglas Fambrough, Dicerna CEO (Dicerna via YouTube)
Novo Nordisk swallows Dicerna and its RNAi pipeline in $3.3B buyout
Early this year researchers at Novo Nordisk were beaming as they announced the first drug identified in their RNAi alliance with Dicerna was headed into …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
